Key facts
- It has raised $187.7M; the latest was Later Stage VC ($77.0M) in Sep 2025.
- Notable investors include HSG (Hong Kong), Aramco Ventures, Sky9 Capital, Lapam Capital, Prosperity7 Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Full-Life Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Full-Life Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Full-Life Technologies
Developer of radiotherapeutic technologies focused on clinical-stage research, production, and commercialisation of radiopharmaceuticals. The company specializes in span radioisotope research, drug development and clinical deployment, serving integrated treatment innovation and addressing key challenges in radiopharmaceutical accessibility and effectiveness.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- full-life.com/
- Ownership
- Privately Held (backing)
Full-Life Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Full-Life Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Full-Life Technologies in its N-PORT filings yet. We sweep new filings monthly.